Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 10/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.39 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.39 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.39 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.39 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.39 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.39 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.39 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409234 | 0.85 | FYN (0.54) | FYNADORA3TTK | |
| SCHEMBL12409242 | 0.84 | TTK (0.56) | FYNADORA3TTKPAX8ATP1A1 | |
| SCHEMBL12409314 | 0.82 | MAPK1 (0.50) | FYNTTK | |
| SCHEMBL12409298 | 0.82 | MAPK1 (0.48) | FYNADORA3TTKPDE10A | |
| SCHEMBL2178662 | 0.82 | TTK (0.48) | FYNADORA3TTKPDE10A | |
| SCHEMBL3470277 | 0.81 | FYN (0.54) | FYNTTK | |
| SCHEMBL12409308 | 0.80 | FYN (0.59) | FYNADORA3TTK | |
| SCHEMBL12409292 | 0.80 | FYN (0.60) | FYNTTK | |
| SCHEMBL12409321 | 0.80 | FYN (0.48) | FYNTTKATP1A1ATP1B1ATP1A3 | |
| SCHEMBL12409252 | 0.79 | ZAP70 (0.48) | FYNTTKPAX8PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | FYN 3511/4885ADORA3 4222/4885TTK 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.